Lymphocytes, Tumor-Infiltrating

TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs

1 month ago talkbio0Tagged Amtagvi, Cell Therapy, Iovance Biotherapeutics, layoffs, Lymphocytes, Tumor-Infiltrating, Malignant neoplasm of lung, melanoma, strategic restructuring, TScan Therapeutics

TScan Therapeutics; layoffs; Iovance Biotherapeutics; Amtagvi; tumor-infiltrating lymphocyte (TIL) therapy; melanoma; lung cancer; strategic restructuring; biotech layoffs; cell therapy

Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints

10 months ago talkbio0Tagged Arenaria, Biological Factors, clinical program, Discontinuation (procedure), Financial cost, Industry, Lymphocytes, Tumor-Infiltrating, Manufacturing, strategic alternatives, TIDAL-01

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma

2 years ago talkbio0Tagged Amtagvi, Lymphocytes, Tumor-Infiltrating, Solid Neoplasm, United States Food and Drug Administration

Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating